Firstly, in the fundamental knowledge (Level I), the neuroendocrine tumor teaching units cover epidemiology, historical evolution, classification, pathology, clinical presentation, and the role of molecular imaging techniques such as PET/CT. Participants will also learn about treatment response evaluation to peptide receptor radionuclide therapy (PRRT) using SPECT/CT and the significance of biomarkers. The prostate cancer units address epidemiology, classification, pathology and genomics, with a particular focus on PSMA PET/CT, including potential pitfalls, PRRT response evaluation using SPECT/CT, and PSA as a tumor marker. Systemic therapy guidelines and the basic principles of PRRT are covered for both tumor types, followed by an introduction to radioiodine therapy in thyroid cancer.

Secondly, the advanced knowledge (Level II) builds on the fundamental concepts through advanced clinical discussions, case-based learning, and international multidisciplinary tumor board (MDTB) illustrations. In prostate cancer, participants will explore the role of bone, choline, PSMA and FDG PET/CT in advanced disease, treatment selection, questions arising from clinical practice, and future directions in theranostics. The neuroendocrine neoplasm units further address NEN biology, molecular imaging, the advanced principles of PRRT, standardized versus personalized treatment approaches, and combination therapy options. Across both disease areas, particular emphasis is placed on multidisciplinary decision-making and the application of knowledge to complex clinical cases.

This pillar explores diverse topics in medical imaging, nuclear medicine and Theranostics targeting an audience of physicists thereby complementing the content of other pillars. Participants may expect to understand SPECT/CT and PET/CT imaging principles, radiobiology and radiotherapy fundamentals, as well as learn about essential topics such as activity measurements, quality control, radiation safety, patient dosimetry and clinical dosimetry and discover strategies to address imaging artifacts and optimize protocols. In summary, participants will appreciate the crucial role of medical physicists in Radiomolecular Precision Oncology.

Addressing chemists and being a great complement to other pillars, this pillar is a strong primer on radiochemistry and nuclear chemistry, exploring the composition of atomic nuclei as a mixture of nucleons, as well as the structure and characteristics of stable and unstable atomic nuclei. Participants will understand the rationale of unstable atom nuclei and the philosophy of nuclear transformation pathways and kinetics. This pillar gives an opportunity to delve into the various emissions specific to individual transformation pathways, in particular relevant to Theranostics. Participants will finally become familiar with radionuclide production processes at nuclear reactors, cyclotrons and generators.

This pillar offers nurses and in general clinicians interacting with patients to acquire basic knowledge and essential skills to effectively support patients in Radiomolecular Precision Oncology. Indeed, nursing plays a crucial role in patient care, thus learning effective patient communication strategies to address their decisions, answer their questions and meet their needs is a major component of the Academy for Theranostics. Moreover, this pillar content explores various therapy video samples to enhance the understanding of procedures and protocols.